ClinicalTrials.gg
RecruitingNCT07951658Updated Nov 20, 2026

Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes

A Phase 1 interventional study of Tirzepatide in Diabetes Type I, sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Phase 1, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.

Planned enrollment
98th of 113
12 · median 153
Started
2026
with 10 others
Phase 1
3 of 150
1 open now
Primary completion
2028-10
later than 28 of 29 live
Registered
150th of 150
by date
Lead sponsor
9 of 150
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 98th largest by planned enrollment of the 113 interventional ones that give a count, is one of 11 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 28 of the 29 other live ones, and was the 150th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, or all of them as a file.
02

Study summary

FAITH-T1D/1, exploratory, Phase I, open-label, non-randomized, single-arm, multicenter clinical trial designed to evaluate the dose-dependent effects of tirzepatide on gastric emptying in adults with type 1 diabetes (T1D) and overweight or obesity.

The study will investigate tirzepatide administered once weekly as an adjunct to participants' usual insulin therapy delivered through automated insulin delivery (AID) systems. Tirzepatide will be administered subcutaneously, with gradual dose escalation from 2.5 mg up to 15 mg at four-week intervals, according to clinical tolerability and the protocol-defined dosing schedule. Its use in this population is off-label.

The study follows a longitudinal, within-subject design in which each participant serves as their own control. Gastric emptying will be assessed by gastric emptying scintigraphy using a standardized solid meal at baseline and at weeks 4, 8, 16 and 24. The primary objective is to characterize changes in gastric emptying in relation to tirzepatide dose. Secondary and exploratory objectives include evaluating metabolic and glycemic parameters, gastrointestinal symptoms, postprandial glucagon, lipidomic and metabolomic profiles, and the safety and tolerability of treatment. Continuous glucose monitoring and AID system data will also be reviewed throughout the study.

The target is 12 evaluable participants, with a maximum of 14 participants allowed to account for early withdrawals before an evaluable post-baseline assessment. The study includes a screening period, approximately 24 weeks of treatment and follow-up assessments through week 30.

Safety assessments will include treatment-emergent adverse events, gastrointestinal symptoms, hypoglycemia and diabetic ketoacidosis, as well as monitoring of tolerability during dose escalation. An independent Data and Safety Monitoring Committee is planned in accordance with the protocol.

The trial will be conducted at two Spanish hospital centers: Hospital Universitario Ramón y Cajal and Hospital Universitari i Politècnic La Fe. The study is exploratory and mechanistic; it is intended to characterize pharmacodynamic effects, estimate within-subject changes and inform the design of future confirmatory studies, rather than establish definitive clinical efficacy.

03

Conditions studied

  • Diabetes Type I
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written : Participants must have received information about the study design, objectives, and potential risks and must provide written informed consent to participate.
  • Ability to comply with study procedures: Ability and willingness to understand the study, comply with the required procedures, and attend all scheduled visits.
  • Age and diagnosis: Age ≥18 years and an established diagnosis of type 1 diabetes mellitus (T1D) for at least 1 year.
  • Stable automated insulin delivery (AID) treatment: Stable treatment with an AID system for at least 90 days before the baseline visit (Visit 0), with a commitment to maintain the same mode of insulin delivery and insulin throughout the study.
  • Baseline : HbA1c between 6.3% and 10.5% at baseline.
  • and weight stability: BMI ≥25 kg/m², with stable body weight (variation ≤5 kg) during at least the 90 days before inclusion.
  • requirements: Participants with must agree to use effective contraception throughout the study and for at least 6 months after the end of the study. The protocol specifies a highly effective contraceptive method plus a barrier method for participants with reproductive potential.

Exclusion criteria

Exclusion Criteria:

Glycemic control and diabetes

  1. Two or more episodes requiring hospitalization for poor glycemic control (hyperglycemia or diabetic ketoacidosis [DKA]) during the 180 days before the baseline visit.
  2. One or more episodes of severe hypoglycemia requiring assistance from another person during the 90 days before baseline.

    Diabetes complications

  3. Active proliferative diabetic retinopathy, or a history of ophthalmologic treatment (photocoagulation, intravitreal injections, or vitrectomy) during the previous 6 months, or anticipated need for such treatment during the 6 months after inclusion.

    Recent cardiovascular disease

  4. Cardiovascular events during the 60 days before baseline, including:

    • Acute myocardial infarction.
    • Stroke.
    • Coronary revascularization.
    • Hospitalization for unstable angina.
    • Heart failure. Gastrointestinal disorders and motility
  5. gastrointestinal disorders, including diabetic gastroparesis.
  6. Previous bariatric surgery.
  7. Chronic use of medications that directly affect gastrointestinal motilityRenal function
  8. Estimated (eGFR) below 15 mL/min/1.73 m² at baseline.

    Neoplasms

  9. Active or malignancy in remission for less than 5 years.
  10. Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).

    Psychiatric disorders

  11. Severe or unstable psychiatric disorders, including uncontrolled major depression, schizophrenia, bipolar disorder, or other severe psychiatric conditions, or severe mood or anxiety disorders during the previous 2 years.

    Concomitant medications

  12. Systemic use for more than 14 days during the 90 days before baseline, excluding replacement therapy.
  13. Use of weight-loss medications or glucose-lowering medications other than insulin during the 90 days before baseline.

  14. Hypersensitivity to tirzepatide or any of its .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Tirzepatide

    Tirzepatide with dose escalation from 2.5 mg to 15 mg.

    Drug: Tirzepatide

Interventions

  • Tirzepatide with dose escalation from 2.5 mg to 15 mg.

06

What researchers measure

Primary outcomes

  1. To characterize the dose-dependent effect of tirzepatide (2.5-15 mg) on gastric emptying (GE) in adults with type 1 diabetes (T1D) and overweight/obesity, assessed as the within-subject change from baseline using gastric emptying scintigraphy (GES).

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24.

Secondary outcomes

  1. Change from baseline in gastric emptying half-time (t½)

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24

  2. Change from baseline in the area under the gastric retention curve over 0-4 hours (AUC₀-₄h).

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24

  3. Change from baseline in gastric retention at 2 hours (%GR-2h).

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24

  4. Change from baseline in gastric retention at 4 hours (%GR-4h).

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24

  5. Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in tight range (70-140 mg/dL)

    Time frame: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase

  6. Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in range (TIR, 70-180 mg/dL)

    Time frame: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase

  7. Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hypoglycemia

    Time frame: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase

  8. Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hyperglycemia

    Time frame: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase

  9. Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including glycemic variability.

    Time frame: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase

  10. Correlation between dose-dependent delays in gastric emptying and improvements in postprandial glucose excursions (TIR, 70-180 mg/dL).

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24; postprandial glucose assessed over the 6 hours following the standardized test meal

  11. Changes in insulin requirements, including total daily insulin dose

    Time frame: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.

  12. Changes in insulin requirements, including the ratio of prandial to basal insulin dose.

    Time frame: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.

  13. Change in HbA1c from baseline to the end of the study.

    Time frame: Baseline (Week 0) and Week 30 (end-of-study visit).

  14. Changes in body weight (kg)

    Time frame: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).

  15. Changes in body mass index (kg/m²)

    Time frame: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).

  16. Changes in waist-to-hip ratio (cm)

    Time frame: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).

  17. Changes in percentage of body fat

    Time frame: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).

  18. Changes from baseline in postprandial glucagon concentrations

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment

  19. Changes from baseline in postprandial lipidomic profiles (Lipoprotein Cholesterol (mg/dL))

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment

  20. Changes from baseline in postprandial lipidomic profiles (Triglycerides (mg/dL))

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment

  21. Changes from baseline in postprandial lipidomic profiles (Particle Number (nmol/L))

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment

  22. Changes from baseline in postprandial lipidomic profiles (Particle Diameter (nm))

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment

  23. Changes from baseline in postprandial metabolomic profiles (Glycoprotein (μmol/L))

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment

  24. Changes from baseline in postprandial metabolomic profiles (LMWM (mmol/L))

    Time frame: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment

  25. Incidence of treatment-emergent adverse events including gastrointestinal symptoms

    Time frame: From the first dose of tirzepatide through the end-of-study visit (Week 30).

  26. Incidence of treatment-emergent adverse events including hypoglycemia

    Time frame: From the first dose of tirzepatide through the end-of-study visit (Week 30).

  27. Incidence of treatment-emergent adverse events including diabetic ketoacidosis

    Time frame: From the first dose of tirzepatide through the end-of-study visit (Week 30).

  28. Tolerability of tirzepatide during dose escalation, assessed by the frequency of dose reductions

    Time frame: During the 24-week treatment period, through Week 24

  29. Tolerability of tirzepatide during dose escalation, assessed by the proportion of participants unable to reach the target dose of 15 mg

    Time frame: During the 24-week treatment period, through Week 24

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2028, 25 months after the start.

Of 55 non-industry phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's planned 25 months is below that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Nov 20, 2026
StartActual
Sep 27, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07951658
Lead sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Collaborators
Hospital Universitario La Fe
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Sep 27, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion